Procurement Summary
Country : USA
Summary : Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)
Deadline : 29 Sep 2020
Other Information
Notice Type : Tender
TOT Ref.No.: 38612140
Document Ref. No. : RFA-CA-20-019
Competition : ICB
Financier : Self Financed
Purchaser Ownership : -
Tender Value : Refer Document
Purchaser's Detail
Purchaser : NATIONAL INSTITUTES OF HEALTH
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
USA
Email :FBOWebmaster@OD.NIH.GOV
Tender Details
Tender are invited for Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)
CFDA Number : 93.394 -- Cancer Detection and Diagnosis Research
Cost Sharing or Matching Requirement : No
Estimated Total Program Funding : $1, 000, 000
Closing Date for Applications: Sep 29, 2020
Posted Date : Dec 04, 2019
Description: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Documents
Tender Notice